

## Data Sharing Statement

Salama C, Han J, Yau L, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. DOI: 10.1056/NEJMoa2030340.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	Qualified researchers may request access to individual patient level data through the clinical study data request platform ( <a href="https://vivli.org/">https://vivli.org/</a> ). Further details on Roche's criteria for eligible studies are available here ( <a href="https://vivli.org/members/ourmembers/">https://vivli.org/members/ourmembers/</a> ) For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here ( <a href="https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm">https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm</a> ).
When will data availability begin?	18 months after completion of study report or regulatory review is completed
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	Roche supports qualified investigators engaged in rigorous, independent scientific research by

	<p>providing access to the data from individual patients participating in studies of products or indications that either (a) are approved by the regulatory authorities, or (b) will not be developed further. Access to Roche’s patient-level data is facilitated through the cross-industry request site <a href="https://vivli.org">https://vivli.org</a>. This platform was designed to enable the sharing of datasets from multiple organisations through a single request process.</p>
For what type of analysis or purpose?	<p>Roche supports qualified investigators engaged in rigorous, independent scientific research by providing access to the data from individual patients participating in studies of products or indications that either (a) are approved by the regulatory authorities, or (b) will not be developed further. Access to Roche’s patient-level data is facilitated through the cross-industry request site <a href="https://vivli.org">https://vivli.org</a>. This platform was designed to enable the sharing of datasets from multiple organisations through a single request process.</p>
By what mechanism?	<p>Roche supports qualified investigators engaged in rigorous, independent scientific research by providing access to the data from individual patients participating in studies of products or indications that either (a) are approved by the regulatory authorities, or (b) will not be developed further. Access to Roche’s patient-level data is facilitated through the cross-industry request site <a href="https://vivli.org">https://vivli.org</a>. This platform was designed to enable the sharing of datasets from multiple organisations through a single request process.</p>
Any other restrictions?	—
Additional information	Everything has been shared above.

This statement was posted on December 17, 2020, at NEJM.org.